HUP0000589A2 - Vizes peptid készítmények - Google Patents

Vizes peptid készítmények

Info

Publication number
HUP0000589A2
HUP0000589A2 HU0000589A HUP0000589A HUP0000589A2 HU P0000589 A2 HUP0000589 A2 HU P0000589A2 HU 0000589 A HU0000589 A HU 0000589A HU P0000589 A HUP0000589 A HU P0000589A HU P0000589 A2 HUP0000589 A2 HU P0000589A2
Authority
HU
Hungary
Prior art keywords
peptides
preparations
aqueous formulations
peptide compound
stable
Prior art date
Application number
HU0000589A
Other languages
English (en)
Inventor
James B. Eckenhoff
Joe Leonard
Steven J. Prestrelski
Cynthia L. Stevenson
Sally A. Tao
Jeremy C. Wright
Original Assignee
Alza Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corporation filed Critical Alza Corporation
Publication of HUP0000589A2 publication Critical patent/HUP0000589A2/hu
Publication of HUP0000589A3 publication Critical patent/HUP0000589A3/hu
Publication of HU225691B1 publication Critical patent/HU225691B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Abstract

A találmány tárgya peptidrőkőn vegyületet tartalmazó stabil vizeskészítmények, amelyek a következőkből állnak: a) legalább körülbelül10% legalább egy peptidvegyület; és b) víz, és az ilyen készítmény 37řC-őn legalább 3 hónapig stabil. A készítmények példáűl implantálhatóhatóanyagleadó eszközökben használhatók. A találmány a készítményekelőállítására szőlgáló eljárásra és a készítmények alkalmazására isvőnatkőzik. ŕ
HU0000589A 1996-07-03 1997-07-01 Aqueous formulations of peptides HU225691B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2119996P 1996-07-03 1996-07-03
PCT/US1997/010816 WO1998000157A1 (en) 1996-07-03 1997-07-01 Aqueous formulations of peptides

Publications (3)

Publication Number Publication Date
HUP0000589A2 true HUP0000589A2 (hu) 2000-09-28
HUP0000589A3 HUP0000589A3 (en) 2001-04-28
HU225691B1 HU225691B1 (en) 2007-06-28

Family

ID=21802912

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0000589A HU225691B1 (en) 1996-07-03 1997-07-01 Aqueous formulations of peptides

Country Status (27)

Country Link
US (2) US5916582A (hu)
EP (1) EP0909177B1 (hu)
JP (2) JP2001504442A (hu)
CN (1) CN1256146C (hu)
AR (1) AR007715A1 (hu)
AT (1) ATE259241T1 (hu)
AU (1) AU3574897A (hu)
BR (1) BR9710131A (hu)
CA (1) CA2259505A1 (hu)
CO (1) CO4890855A1 (hu)
CZ (1) CZ298464B6 (hu)
DE (1) DE69727572T2 (hu)
ES (1) ES2213828T3 (hu)
HK (1) HK1020677A1 (hu)
HU (1) HU225691B1 (hu)
ID (1) ID19305A (hu)
IL (1) IL127770A (hu)
MY (1) MY125556A (hu)
NO (1) NO323296B1 (hu)
NZ (1) NZ333579A (hu)
PL (1) PL189403B1 (hu)
RO (1) RO120611B1 (hu)
RU (1) RU2201248C2 (hu)
SK (1) SK284283B6 (hu)
TW (1) TW586932B (hu)
WO (1) WO1998000157A1 (hu)
ZA (1) ZA975943B (hu)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1716884T3 (en) 1998-10-29 2014-03-10 Medtronic Minimed Inc reservoir Connection
US6248093B1 (en) 1998-10-29 2001-06-19 Minimed Inc. Compact pump drive system
US7193521B2 (en) 1998-10-29 2007-03-20 Medtronic Minimed, Inc. Method and apparatus for detecting errors, fluid pressure, and occlusions in an ambulatory infusion pump
US6800071B1 (en) 1998-10-29 2004-10-05 Medtronic Minimed, Inc. Fluid reservoir piston
US20020173748A1 (en) 1998-10-29 2002-11-21 Mcconnell Susan Reservoir connector
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US7063684B2 (en) 1999-10-28 2006-06-20 Medtronic Minimed, Inc. Drive system seal
CA2507524C (en) * 2002-09-27 2012-12-11 Zentaris Gmbh Administration form for pharmaceutically active peptides with sustained release and method for the production thereof
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
US20060039949A1 (en) * 2004-08-20 2006-02-23 Nycz Jeffrey H Acetabular cup with controlled release of an osteoinductive formulation
US20060045902A1 (en) * 2004-09-01 2006-03-02 Serbousek Jon C Polymeric wrap for in vivo delivery of osteoinductive formulations
US20060057184A1 (en) * 2004-09-16 2006-03-16 Nycz Jeffrey H Process to treat avascular necrosis (AVN) with osteoinductive materials
EP1838290A2 (en) * 2005-01-21 2007-10-03 Alza Corporation Therapeutic peptide formulations for coating microneedles with improved stability containing at least one counterion
US8137664B2 (en) * 2005-02-02 2012-03-20 Sdgi Holdings, Inc. Method and kit for repairing a defect in bone
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
ES2365410T3 (es) * 2005-04-08 2011-10-04 Amylin Pharmaceuticals, Inc. Formulaciones farmacéuticas que comprenden péptido de incretina y un disolvente polar aprótico.
CN100336557C (zh) * 2005-05-11 2007-09-12 北京双鹭药业股份有限公司 一种生长抑素的水溶液制剂、其制备方法及应用
US20060293243A1 (en) * 2005-06-17 2006-12-28 Navneet Puri Stable, buffered, pharmaceutical compositions including motilin-like peptides
US20060287243A1 (en) * 2005-06-17 2006-12-21 Navneet Puri Stable pharmaceutical compositions including motilin-like peptides
BRPI0710503A2 (pt) * 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
ES2351527T3 (es) 2006-05-30 2011-02-07 Intarcia Therapeutics, Inc Modulador de flujo en dos piezas con conducto interno para un sistema osmótico de administración.
NZ574524A (en) 2006-08-09 2011-07-29 Intarcia Therapeutics Inc Piston assembly for positioning lumen of a reservoir for an osmotic delivery having a columnar body and a spring
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
US8968786B2 (en) 2007-06-22 2015-03-03 Board Of Regents, The University Of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
KR20100061486A (ko) * 2007-09-11 2010-06-07 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드의 용도
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
KR20110007242A (ko) * 2008-05-07 2011-01-21 메리온 리서치 Ⅲ 리미티드 펩티드 조성물 및 그의 제조 방법
MX2020005326A (es) 2008-08-15 2022-03-03 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para administracion oral.
JP5711138B2 (ja) 2008-11-16 2015-04-30 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 高濃度の低粘度懸濁液
EP2400851A4 (en) * 2009-02-25 2012-09-05 Merrion Res Iii Ltd COMPOSITION AND ACTIVE COMPOSITION OF BISPHOSPHONATES
EP2246063A1 (en) * 2009-04-29 2010-11-03 Ipsen Pharma S.A.S. Sustained release formulations comprising GnRH analogues
MX2012001660A (es) 2009-08-06 2012-03-26 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para adminstracion oral.
LT2462246T (lt) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011103311A2 (en) 2010-02-17 2011-08-25 Ironwood Pharmaceuticals, Inc Treatments for gastrointestinal disorders
WO2011120033A1 (en) * 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
US20140005128A1 (en) 2010-08-11 2014-01-02 Forest Laboratories Holdings Limited Treatments of gastrointestinal disorders
WO2012094598A2 (en) 2011-01-07 2012-07-12 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2776055B1 (en) 2011-08-17 2016-12-14 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US10112987B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
EP2832361A1 (en) * 2013-07-29 2015-02-04 Ipsen Pharma S.A.S. Aqueous sustained release compositions of LHRH analogs
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CN107205948B (zh) 2015-01-29 2021-12-14 诺和诺德股份有限公司 包含glp-1激动剂和肠溶衣的片剂
JP6993235B2 (ja) 2015-06-03 2022-01-13 インターシア セラピューティクス，インコーポレイティド インプラントの設置及び撤去システム
CN105749245A (zh) * 2016-03-02 2016-07-13 张光泉 抗癌药醋酸地加瑞克注射液及其制备方法
EP3458084B1 (en) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914412A (en) * 1973-10-11 1975-10-21 Abbott Lab {8 Des{13 Gly{9 {0 10 -Gn{13 RH nonapeptide amide analogs in position 6 having ovulation-inducing activity
US4248864A (en) * 1979-08-30 1981-02-03 American Home Products Corporation Reproduction control
JPH0625068B2 (ja) * 1982-12-10 1994-04-06 シンテツクス（ユ−・エス・エ−・）インコ−ポレイテイド 鼻腔内投与用組成物及びその製造方法
US4547370A (en) * 1983-11-29 1985-10-15 The Salk Institute For Biological Studies GnRH Antagonists
US4661472A (en) * 1985-05-09 1987-04-28 The Salk Institute For Biological Studies GnRH antagonists IX
US4851385A (en) * 1987-07-15 1989-07-25 Indiana University Foundation LHRH antagonist analogs having low histamine-release activity
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
DD273980B5 (de) * 1988-07-12 1994-04-14 Berlin Chemie Ag Verfahren zur Herstellung von Insulin-Pr{paraten zur rektalen Anwendung
US5034229A (en) * 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
US5110596A (en) * 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
US5057318A (en) * 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
DE4117507A1 (de) * 1991-05-24 1992-11-26 Schering Ag Verfahren zur herstellung von n(pfeil hoch)6(pfeil hoch)-substituierten lysin-derivaten
US5446025A (en) * 1992-06-12 1995-08-29 Abbott Laboratories Formulations and method of the percutaneous administration of leuprolide
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
JP3698721B2 (ja) * 1993-02-23 2005-09-21 ジェネンテク・インコーポレイテッド 有機溶媒を用いて処理したポリペプチドの賦形剤安定化
DE4320201A1 (de) * 1993-06-18 1995-01-12 Asta Medica Ag Verwendung von Cetrorelix und weiteren Nona- und Dekapeptiden zur Herstellung eines Arzneimittels zur Bekämpfung von Aids und zur Wachstumsstimulation
HU221617B1 (hu) * 1993-06-29 2002-12-28 Ferring B.V. Vizes készítmény dezmopresszin nazális adagolására
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
US5413990A (en) * 1993-08-06 1995-05-09 Tap Pharmaceuticals Inc. N-terminus modified analogs of LHRH
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
WO1997027840A1 (en) * 1996-02-02 1997-08-07 Alza Corporation Sustained delivery of an active agent using an implantable system

Also Published As

Publication number Publication date
NO323296B1 (no) 2007-03-05
IL127770A (en) 2006-10-31
SK284283B6 (sk) 2005-01-03
HK1020677A1 (en) 2000-05-19
AR007715A1 (es) 1999-11-10
CN1256146C (zh) 2006-05-17
WO1998000157A1 (en) 1998-01-08
TW586932B (en) 2004-05-11
PL189403B1 (pl) 2005-08-31
PL330903A1 (en) 1999-06-07
HUP0000589A3 (en) 2001-04-28
NO986208D0 (no) 1998-12-30
US6068850A (en) 2000-05-30
CZ298464B6 (cs) 2007-10-10
HU225691B1 (en) 2007-06-28
EP0909177B1 (en) 2004-02-11
JP2008291037A (ja) 2008-12-04
DE69727572T2 (de) 2004-12-16
EP0909177A1 (en) 1999-04-21
JP2001504442A (ja) 2001-04-03
CN1224357A (zh) 1999-07-28
CA2259505A1 (en) 1998-01-08
ATE259241T1 (de) 2004-02-15
ID19305A (id) 1998-07-02
NO986208L (no) 1998-12-30
AU3574897A (en) 1998-01-21
BR9710131A (pt) 1999-08-10
RO120611B1 (ro) 2006-05-30
US5916582A (en) 1999-06-29
ZA975943B (en) 1998-04-16
SK179898A3 (en) 1999-06-11
CO4890855A1 (es) 2000-02-28
CZ433998A3 (cs) 1999-04-14
MY125556A (en) 2006-08-30
DE69727572D1 (de) 2004-03-18
IL127770A0 (en) 1999-10-28
ES2213828T3 (es) 2004-09-01
NZ333579A (en) 2000-06-23
RU2201248C2 (ru) 2003-03-27

Similar Documents

Publication Publication Date Title
HUP0000589A2 (hu) Vizes peptid készítmények
HUP9901893A2 (hu) Új, stabil, folyékony paracetamolkészítmények
HUP0003592A2 (hu) LH-RH peptid analógok, alkalmazásuk, és ezeket tartalmazó gyógyászati készítmények
AU6819294A (en) Oral drug delivery compositions and methods
MY101791A (en) New benzimidazole derivatives
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
HUP9903942A2 (hu) Nemvizes protikus peptid készítmények
DK0458894T3 (da) Lipidexcipiens til nasal afgivelse og topisk påføring
HUP0001293A1 (hu) Heterociklusos vegyületek és ezeket tartalmazó gyógyászati készítmények béta-amiloid-peptidek gátlására
MY121908A (en) 3-amidopyrazole derivatives, process for preparing these and pharmaceutical compositions containing them.
IS4146A (is) Lyfjablanda til að gefa dýrum um munn sem inniheldur prótonupumpublokkara
DE69417252T2 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
ATE73459T1 (de) Pharmazeutische zusammensetzungen, welche ein dipeptid enthalten.
HUP9903906A2 (hu) Kelátképző clioquinol felhasználása Alzheimer-kór kezelésére alkalmas gyógyszerkészítmények előállításánál
HUP0301349A2 (hu) IL-11-tartalmú készítmények
SE8804570L (sv) Ciclosporinkristallform, foerfarande foer dess framstaellning, farmaceutiska kompositioner innehaallande densamma samt dess anvaendning
KR890700125A (ko) 신규 벤즈이미다졸 유도체, 그 제조방법 및 이 화합물을 함유하는 제약 조성물
HUP0000432A2 (hu) Inzulin C-peptidek
DE3583916D1 (de) Waessrige arzneiformulierungen des piroxicammonohydrats.
HUP9602498A2 (hu) Antimikrobiális hatású gyógyászati készítmények
EP0173664A3 (en) Biologically active benzimidazole compounds and process for their preparation
MX9504023A (es) Composicion farmaceutica y transdermicamente activa que contiene acido 5-aminolaevulinico y procedimiento para su preparacion.
SE9403389D0 (sv) Pharmaceutical composition containing derivattves of sex hormones
HUP0000812A2 (hu) Myelin bázikus fehérje peptid-fragmentumai az azokat tartalmazó gyógyszerkészítmények és felhasználásuk a sclerosis multiplex kezelésére
IT8521528A0 (it) Composizioni farmaceutiche e cosmetiche contenenti come ingrediente attivo diidrossi-1,8fenil-10 antrone-9, e procedimentodi preparazione dell'ingrediente attivo.

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees